| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ForGrowth III PA B.V. | 10% | 0% | $81,492,203 | +$25,772,203 | 10,237,714 | +46% | ForGrowth III PA B.V. | 18 Dec 2025 |
| RA CAPITAL MANAGEMENT, L.P. | 14% | +41% | $43,075,707 | +$24,407,302 | 5,411,521 | +131% | RA Capital Management, L.P. | 18 Dec 2025 |
| Frazier Life Sciences Public Fund, L.P. | 5.8% | $17,973,688 | 2,258,001 | Frazier Life Sciences Public Fund, L.P. | 18 Dec 2025 | |||
| Paradigm Biocapital Advisors LP | 8.6% | $43,750,000 | 1,750,000 | Paradigm BioCapital Advisors LP | 11 Nov 2025 | |||
| GREAT POINT PARTNERS LLC | 5.6% | $9,826,509 | 1,234,486 | Great Point Partners, LLC | 10 Dec 2025 | |||
| Reprogrammed Interchange LLC | 18% | $48,045,191 | 1,204,442 | Reprogrammed Interchange LLC | 15 Oct 2025 | |||
| FMR LLC | 12% | $38,391,298 | 788,447 | FMR LLC | 31 Oct 2025 | |||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | 760,699 | Venrock Healthcare Capital Partners III, L.P. | 18 Sep 2025 | ||||
| Verve Capital Ltd | 9.9% | 760,699 | Verve Capital Limited | 18 Sep 2025 | ||||
| Qiming Venture Partners VIII-HC, L.P. | 5.4% | $1,210,904 | 496,272 | Qiming Venture Partners VIII-HC, L.P. | 18 Sep 2025 |
As of 30 Sep 2025, 36 institutional investors reported holding 3,764,070 shares of Vor Biopharma Inc. - Common Stock, $0.0001 par value per share (VOR). This represents 3.7% of the company’s total 102,479,620 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 3,764,070 | $183,385,609 | +$183,089,635 | $48.72 | 36 |